Mental Health Clinics in E Wenatchee, WA Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 Barrier & Associates, Inc. Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 230 Grant Rd Ste Cb1, E Wenatchee, WA 98802 Phone: 509-884-1020 Fax: 509-886-9290 |
Barrier & Associates Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 230 Grant Rd Ste Cb1, E Wenatchee, WA 98802 Phone: 509-884-1020 Fax: 509-886-9290 |
News Archive
Experts identify efficient way to increase minority access to colorectal cancer screening
Minority patients have a significantly decreased survival from colon cancer compared to white patients, most often as a result of a late diagnosis. To help address this problem, a team of healthcare professionals at Memorial Sloan-Kettering Cancer Center has identified an efficient way to increase minority access to lifesaving colorectal cancer screening (CRCS) in communities where multiple barriers to preventive care exist.
New guidance on treating COVID-19 patients with heart attack signs
Much remains unknown about COVID-19, but many studies already have indicated that people with cardiovascular disease are at greater risk of COVID-19.
DNA weak links may provide clues to cancer biology
The chromosomes of mammals, including humans, contain regions that are particularly prone to breaking under conditions of stress and in cancer. Now, new research by geneticists at Duke University Medical Center finds that yeast cells also contain such weak links in DNA and begins to reveal the molecular characteristics of these links that might help to explain them.
Neuropsychopharmacology editor resigns after failure to disclose conflict of interest
Charles Nemeroff has decided to resign as editor of the journal Neuropsychopharmacology after he co-authored a favorable article on a chest implant that treats depression and did not disclose his financial ties to Cyberonics, which manufactures the device, the Wall Street Journal reports.
Canopus BioPharma enters phase II clinical trials with CB1400
Canopus BioPharma, Inc. has announced that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis. This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent.
› Verified 2 days ago